Hammersmith Medicines Research (HMR)
London, United Kingdom
NCT Number: NCT03646331
This is an open-label assessment of the bioequivalence of two 500 mg-tablet formulations of imeglimin (Tablet A [reference product] and Tablet B [test product]), in at least 16 healthy Caucasian volunteers.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
London, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Reference product
Test product (new formulation tablet)
Time frame: from dosing up to 48h
Cmax: peak plasma concentration after dosing
Time frame: from dosing up to 48h
AUC last: area Under the concentration time curve
Time frame: From Day 1 to Day 15
Incidence of treatment emergent adverse events
Looking for future studies?
Notify MePoxel SA
Industry
A Phase I, Open-label, Randomised, Single-centre, 2-way Crossover Bioequivalence Study Comparing 2 Formulations of Imeglimin After Single Oral Doses in Healthy Caucasian Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07345130
Bioavailability, Bioequivalence
Las Vegas, Nevada, United States
View Trial DetailsNCT07769359
Adhesion, Adverse Effects
Vadodara, Gujarat, India
View Trial DetailsNCT07763912
Bioequivalence
Mexico City, Mexico
View Trial DetailsNCT07698288
Bioequivalence
Mexico City, Mexico
View Trial Details